
Detail-oriented Molecular Pathology Technologist with hands-on experience performing complex molecular assays to support accurate diagnosis and patient care. Proficient in DNA/RNA extraction, ddPCR, real-time qPCR, Next-Generation Sequencing (NGS), Sanger Sequencing workflows, and other advanced molecular diagnostic techniques. Skilled in maintaining and troubleshooting high-throughput instrumentation while ensuring strict adherence to CLIA and CAP quality standards. Experienced in interpreting QC metrics, maintaining meticulous documentation, and supporting assay validation and optimization. Currently training to become a CAP inspector, bringing a strong understanding of regulatory compliance and laboratory best practices. Known for excellent organization, precision, and effective collaboration with pathologists, technologists, and multidisciplinary laboratory teams to support accurate, high-quality molecular diagnostics.
Additional responsibilities amongst those listed below:
Quality assurance
Microbiological analysis
Molecular diagnostics
Laboratory information systems
Cell culture techniques
Gel electrophoresis
Western blotting
Immunohistochemistry
Nucleic acid sequencing
PCR analysis
Protein precipitation
Cincinnati Children's Hospital Medical Center
Molecular and Genomic Pathology Services Laboratory
1. In the MGPS lab, one of my research projects is designing a sanger sequencing assay for the detection of hotspot mutations in the CTNNB1gene. CTNNB1 hotspot mutations primarily target exon 3, specifically serine and threonine residues. These residues are crucial phosphorylation sites for GSK-3β, preventing β-catenin degradation thus leading to uncontrolled Wnt pathway activation in liver, colorectal, and endometrial cancers. These mutations stabilize nuclear β-catenin, driving tumor growth, with hotspots often clustered in codons 32–37 and 41–45. This project involves primer/probe design, cycle sequencing, capillary electrophoresis, assay optimization, quality assurance and formulating a standard operating procedure.
2. Another minor project I am working on is the Qiagen elution volume project. In the MGPS lab, we have two methods of extracting nucleic acid from samples for infectious disease testing; via silica-based columns (Qiagen) or magnetic beads (MagnaPure). Currently, both methods have different elution volumes (200uL and 100uL), and research has shown this causes a significant difference in quantities reported for our various qPCR assays. I am currently gathering data to standardize both volumes to 100uL, with the goal of reporting the same quantities no matter the extraction method used.
Lehigh University Distance Education-from January 2024 to August 2024
The Vontz Center for Molecular Studies at the University of Cincinnati (The Du lab)- from September 2019 to May 2020